Jannat Khoshnur, Paul Alok K, Bondhon Tohmina A, Hasan Anamul, Nawaz Muhammad, Jahan Rownak, Mahboob Tooba, Nissapatorn Veeranoot, Wilairatana Polrat, Pereira Maria de Lourdes, Rahmatullah Mohammed
Department of Biotechnology & Genetic Engineering, University of Development Alternative, Lalmatia, Dhaka 1207, Bangladesh.
School of Pharmacy and Pharmacology, University of Tasmania, Hobart, TAS 7001, Australia.
Pharmaceutics. 2021 Nov 8;13(11):1895. doi: 10.3390/pharmaceutics13111895.
Recent years have witnessed the emergence of several viral diseases, including various zoonotic diseases such as the current pandemic caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Other viruses, which possess pandemic-causing potential include avian flu, Ebola, dengue, Zika, and Nipah virus, as well as the re-emergence of SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) coronaviruses. Notably, effective drugs or vaccines against these viruses are still to be discovered. All the newly approved vaccines against the SARS-CoV-2-induced disease COVID-19 possess real-time possibility of becoming obsolete because of the development of 'variants of concern'. Flavonoids are being increasingly recognized as prophylactic and therapeutic agents against emerging and old viral diseases. Around 10,000 natural flavonoid compounds have been identified, being phytochemicals, all plant-based. Flavonoids have been reported to have lesser side effects than conventional anti-viral agents and are effective against more viral diseases than currently used anti-virals. Despite their abundance in plants, which are a part of human diet, flavonoids have the problem of low bioavailability. Various attempts are in progress to increase the bioavailability of flavonoids, one of the promising fields being nanotechnology. This review is a narrative of some anti-viral dietary flavonoids, their bioavailability, and various means with an emphasis on the nanotechnology system(s) being experimented with to deliver anti-viral flavonoids, whose systems show potential in the efficient delivery of flavonoids, resulting in increased bioavailability.
近年来,出现了几种病毒性疾病,包括各种人畜共患病,如由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的当前大流行疾病。其他具有大流行潜力的病毒包括禽流感、埃博拉、登革热、寨卡和尼帕病毒,以及SARS(严重急性呼吸综合征)和MERS(中东呼吸综合征)冠状病毒的再次出现。值得注意的是,针对这些病毒的有效药物或疫苗仍有待发现。所有新批准的针对SARS-CoV-2引起的疾病COVID-19的疫苗,由于“关注变体”的出现,都有可能随时过时。黄酮类化合物越来越被认为是预防和治疗新出现的和旧的病毒性疾病的药物。已鉴定出约10000种天然黄酮类化合物,它们都是植物化学物质,全部基于植物。据报道,黄酮类化合物的副作用比传统抗病毒药物小,并且比目前使用的抗病毒药物对更多的病毒性疾病有效。尽管它们在作为人类饮食一部分的植物中含量丰富,但黄酮类化合物存在生物利用度低的问题。目前正在进行各种尝试来提高黄酮类化合物的生物利用度,其中一个有前景的领域是纳米技术。这篇综述讲述了一些具有抗病毒作用的膳食黄酮类化合物、它们的生物利用度以及各种方法,重点是正在试验的用于递送抗病毒黄酮类化合物的纳米技术系统,这些系统在有效递送黄酮类化合物方面显示出潜力,从而提高了生物利用度。